Literature DB >> 11566615

Prospects for phosphoinositide 3-kinase inhibition as a cancer treatment.

R C Stein1.   

Abstract

The phosphoinositide 3-kinases (PI3-kinases) are a family of lipid kinases that have a key role in the regulation of many cellular processes including proliferation, survival, carbohydrate metabolism, and motility. There is now strong evidence that some members of the PI3-kinase family have an important role in cancer. Emerging evidence for functional specialisation of PI3-kinase isoforms suggests that isoform selective inhibitors, in contrast to the existing non-selective inhibitors wortmannin and LY294002, may prove to be useful anticancer drugs.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11566615     DOI: 10.1677/erc.0.0080237

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  27 in total

1.  Akt-mediated phosphorylation of CDK2 regulates its dual role in cell cycle progression and apoptosis.

Authors:  Subbareddy Maddika; Sudharsana Rao Ande; Emilia Wiechec; Lise Lotte Hansen; Sebastian Wesselborg; Marek Los
Journal:  J Cell Sci       Date:  2008-04-01       Impact factor: 5.285

2.  The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts.

Authors:  Nathan T Ihle; Gillian Paine-Murrieta; Margareta I Berggren; Amanda Baker; Wendy R Tate; Peter Wipf; Robert T Abraham; D Lynn Kirkpatrick; Garth Powis
Journal:  Mol Cancer Ther       Date:  2005-09       Impact factor: 6.261

Review 3.  Signaling pathways as therapeutic targets in biliary tract cancer.

Authors:  Jennifer Yang; Matthew R Farren; Daniel Ahn; Tanios Bekaii-Saab; Gregory B Lesinski
Journal:  Expert Opin Ther Targets       Date:  2017-03-17       Impact factor: 6.902

4.  Sex differences in the mechanism of Met5-enkephalin-induced cardioprotection: role of PI3K/Akt.

Authors:  Zhiping Cao; Lijuan Liu; William Packwood; Matthias Merkel; Patricia D Hurn; Donna M Van Winkle
Journal:  Am J Physiol Heart Circ Physiol       Date:  2007-11-02       Impact factor: 4.733

5.  Cisplatin-induced macroautophagy occurs prior to apoptosis in proximal tubules in vivo.

Authors:  Kosuke Inoue; Hitoshi Kuwana; Yoshiko Shimamura; Koji Ogata; Yoshinori Taniguchi; Toru Kagawa; Taro Horino; Toshihiro Takao; Tatsuhito Morita; Sei Sasaki; Noboru Mizushima; Yoshio Terada
Journal:  Clin Exp Nephrol       Date:  2009-12-15       Impact factor: 2.801

6.  Mechanisms underlying the metabolic actions of galegine that contribute to weight loss in mice.

Authors:  M H Mooney; S Fogarty; C Stevenson; A M Gallagher; P Palit; S A Hawley; D G Hardie; G D Coxon; R D Waigh; R J Tate; A L Harvey; B L Furman
Journal:  Br J Pharmacol       Date:  2008-02-25       Impact factor: 8.739

Review 7.  Targeting PI3K signalling in cancer: opportunities, challenges and limitations.

Authors:  Jeffrey A Engelman
Journal:  Nat Rev Cancer       Date:  2009-08       Impact factor: 60.716

Review 8.  Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway.

Authors:  Todd M Morgan; Theodore D Koreckij; Eva Corey
Journal:  Curr Cancer Drug Targets       Date:  2009-03       Impact factor: 3.428

Review 9.  Resistance mechanisms of tumour cells to EGFR inhibitors.

Authors:  F Morgillo; F Cantile; M Fasano; T Troiani; E Martinelli; F Ciardiello
Journal:  Clin Transl Oncol       Date:  2009-05       Impact factor: 3.405

10.  Akt is transferred to the nucleus of cells treated with apoptin, and it participates in apoptin-induced cell death.

Authors:  S Maddika; G H Bay; T J Kroczak; S R Ande; S Maddika; E Wiechec; S B Gibson; M Los
Journal:  Cell Prolif       Date:  2007-12       Impact factor: 6.831

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.